Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,983 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study.
Mhawech-Fauceglia P, McCarthy D, Tonooka A, Scambia G, Garcia Y, Dundr P, Mills AM, Moore K, Sanada S, Bradford L, Stella GC, Bookman M, Sharma SK, Selle F, Molinero L, He Y, Khor V, Landen C, Lin YG. Mhawech-Fauceglia P, et al. Among authors: scambia g. Gynecol Oncol. 2024 Mar 29;186:17-25. doi: 10.1016/j.ygyno.2024.03.022. Online ahead of print. Gynecol Oncol. 2024. PMID: 38554625 Free article.
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators. Gonzalez-Martin A, et al. Among authors: scambia g. Eur J Cancer. 2013 Dec;49(18):3831-8. doi: 10.1016/j.ejca.2013.08.002. Epub 2013 Sep 2. Eur J Cancer. 2013. PMID: 24007819 Clinical Trial.
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Makker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, Regináčová K, Richardson DL, Perri T, Oza AM, Miller DS, Alía EMG, De Giorgi U, Henry S, Spitz DL, Wimberger P, Bednaříková M, Chon HS, Martínez-Garcia J, Pisano C, Berek JS, Romero I, Scambia G, Fariñas-Madrid L, Buscema J, Schochter F, Li K, Kalyanapu P, Walker CJ, Vergote I. Makker V, et al. Among authors: scambia g. Gynecol Oncol. 2024 Jun 3:S0090-8258(24)00234-8. doi: 10.1016/j.ygyno.2024.05.016. Online ahead of print. Gynecol Oncol. 2024. PMID: 38834399
Identification of a False-positive Multiplex Ligationdependent Probe Amplification Result in BRCA1 Using a Copy Number Variation Algorithm Under Development for a Commercial Next-Generation Sequencing-based Homologous Recombination Deficiency Assay.
Concolino P, De Paolis E, Rinelli M, Maneri G, Brisighelli F, Trozzi R, Duranti S, Giacò L, Piane M, Preziosi A, Panfili A, Scambia G, Nero C, De Bonis M, Minucci A. Concolino P, et al. Among authors: scambia g. Ann Lab Med. 2024 May 31. doi: 10.3343/alm.2024.0051. Online ahead of print. Ann Lab Med. 2024. PMID: 38826062 Free article. No abstract available.
How deep is too deep? Assessing myometrial invasion as a predictor of distant recurrence in stage I endometrioid endometrial cancer.
Dinoi G, Garzon S, Weaver A, McGree M, Glaser G, Langstraat C, Kumar A, Weroha J, Garda AE, Shahi M, Palmieri E, Scambia G, Fanfani F, Mariani A. Dinoi G, et al. Among authors: scambia g. Int J Gynecol Cancer. 2024 May 30:ijgc-2023-005217. doi: 10.1136/ijgc-2023-005217. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38821549
Application of novel algorithm on a retrospective series to implement the molecular classification for endometrial cancer.
Arcieri M, Vizzielli G, Occhiali T, Giorgiutti C, Tius V, Pregnolato S, Mariuzzi L, Orsaria M, Tulisso A, Damante G, D'Elia AV, Cucinella G, Chiantera V, Fanfani F, Ercoli A, Driul L, Scambia G, Restaino S. Arcieri M, et al. Among authors: scambia g. Eur J Surg Oncol. 2024 May 23;50(7):108436. doi: 10.1016/j.ejso.2024.108436. Online ahead of print. Eur J Surg Oncol. 2024. PMID: 38820923 Free article.
Author's reply to correspondence on "Expanding the Use of HIPEC in Ovarian Cancer at Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis and Perioperative and Oncologic Outcomes" by Mukurdipi Ray et al.
Ghirardi V, Trozzi R, Scambia G, Fagotti A. Ghirardi V, et al. Among authors: scambia g. Ann Surg Oncol. 2024 May 30. doi: 10.1245/s10434-024-15503-6. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38814550 No abstract available.
Epithelial ovarian cancer and brain metastases: might the BRCA status, PARP inhibitor administration, and surgical treatment impact the survival?
Sassu CM, Marchetti C, Russo G, Minucci A, Boccia SM, Benato A, Nero C, Piermattei A, Mattogno PP, Giannarelli D, Ferrandina G, Olivi A, Fagotti A, Scambia G. Sassu CM, et al. Among authors: scambia g. Int J Gynecol Cancer. 2024 Jan 5;34(1):88-98. doi: 10.1136/ijgc-2023-004980. Int J Gynecol Cancer. 2024. PMID: 38805344
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
Roma C, Esposito Abate R, Sacco A, Califano D, Arenare L, Bergantino F, Pisano C, Cecere SC, Scambia G, Lorusso D, Artioli G, Tasca G, Spina A, Russo D, Gadducci A, De Angelis C, Bologna A, Marchini S, Capoluongo ED, Perrone F, Pignata S, Normanno N. Roma C, et al. Among authors: scambia g. Eur J Cancer. 2024 May 23;206:114127. doi: 10.1016/j.ejca.2024.114127. Online ahead of print. Eur J Cancer. 2024. PMID: 38797038
1,983 results